FERNANDINA BEACH, FL – Dr. Mark A. Munger, Professor of Pharmacotherapy and Adjunct Professor of Internal Medicine at the University of Utah, joins the growing advisory board at GalenusRx, a leader in precision medication safety with decades of experience and one of the USA TODAY Network’s 2024 “Florida startups to watch.”
An international speaker and author whose 300-plus manuscripts and abstracts have been cited more than 32,000 times, Dr. Munger brings vast experience in human cardiovascular physiology and pharmacology, human research regulatory affairs, and professional pharmacy matters.
“Our advisory board takes another important leap with the addition of Mark A. Munger,” said Jacques Turgeon, PhD, Co-CEO and Chief Scientific Officer, GalenusRx. “His innovative research and history of academic excellence will bring insight, inspiration, and important perspective to GalenusRx’s growth. We’re honored that he’s committed to supporting our goal of revolutionizing medication safety with the power of precision.”
A member of the University of Utah faculty since 1991, Dr. Munger is also a fellow in the school’s Academy of Health Science Educators. The American College of Clinical Pharmacy, the American College of Cardiology, and the Heart Failure Society of America count among his other highly respected fellowships.
In addition to his seven-year tenure as the University of Utah’s Institutional Review Board Chairman, Dr. Munger formerly chaired the Utah State Board of Pharmacy, the Utah State Department of Health Digital Health Commission, and the Utah State Controlled Substances Advisory Board.
His ongoing research includes a focus on repurposing and advancing drugs for new therapeutic indications and developing community pharmacy into an integrated model of healthcare delivery.
“Teaming with GalenusRx as an advisor is an exciting opportunity and an excitingly appropriate fit,” Dr. Munger said. “As an educator, I’m immersed in the future of pharmacotherapy. I see our current shortcomings and the possibilities that tomorrow holds. I’m focused on building a better tomorrow, and so is GalenusRx. I know we’ll do great things together.”
GalenusRx’s proprietary medication safety analytics platform, APPRAISE™, provides comprehensive risk assessments by analyzing drug-drug, multi-drug, drug-gene, and drug-disease interactions. This innovation ensures that patients receive the safest and most effective medication regimens, optimized and personalized for each individual.
